Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery.

In the pooled phase 3 trials, inhaled liposomal ciprofloxacin resulted in a delay in the time to first exacerbation of 65 days, which did not reach statistical significance (HR = 0.82 and p = 0.074); however, the frequency of moderate to severe pulmonary exacerbations (PE) was significantly ( p = 0.0001) reduced by 33% and the frequency of severe PEs was significantly ( p = 0.014) reduced by 42% [ 136 ].

also in 111,027 other papers